Moorfields and UCL Institute of Ophthalmology: Thinner retinas are an early sign of cognitive decline

26 July 2018
Source: Moorfields

Researchers from Moorfields and the UCL Institute of Ophthalmology (UCL IoO) have found that thinner retinas in the human eye are a clear sign a person is at significant and increased risk of future mental decline. This breakthrough study co-authored by Prof Paul Foster, Professor of Glaucoma Studies  at UCL IoO and Moorfields, and Mr Praveen Patel, consultant ophthalmic surgeon

Read more Moorfields and UCL Institute of Ophthalmology: Thinner retinas are an early sign of cognitive decline

Macular Society: Treatment trial for Stargardt diseases reaches the UK

12 February 2018
Source: Macular Society

Researchers in the south of England will become the first in the UK to trial a new drug that could prevent sight loss caused by Stargardt disease, a currently untreatable condition. Stargardt disease, also known as Stargardt macular dystrophy, affects the area of the retina called the macula and causes a reduction in central vision. It is the most common form of juvenile macular

Read more Macular Society: Treatment trial for Stargardt diseases reaches the UK

The Guardian: US drug firm offers cure for blindness – at $425,000 an eye. With comment from RP Fighting Blindness

4 January 2018

Spark Therapeutics says ‘responsible price’ for Luxturna gene therapy ensures access for patients with retinal defect. A drug whose inventors claim it can cure a rare form of blindness is to be one of the most expensive medicines ever sold at $850,000 (£630,000). Luxturna is injected directly into the eye to address the root cause of visual impairment by replacing

Read more The Guardian: US drug firm offers cure for blindness – at $425,000 an eye. With comment from RP Fighting Blindness

Optometry Today: Gene Editing Halts Vision Loss in Mice

18 August 2017
Source: Optometry Today

Researchers prevent abnormal blood vessel growth in the retina Scientists from the Schepens Eye Research Institute have prevented mice from developing angiogenesis of the retina using the gene-editing technique, CRISPR-Cas9. Angiogenesis involves the abnormal growth of blood cells on the surface of the retina. It occurs in several degenerative eye conditions including proliferative diabetic retinopathy, wet age-related macular degeneration and

Read more Optometry Today: Gene Editing Halts Vision Loss in Mice